OP
HRTX icon

ORG Partners’s Heron Therapeutics HRTX Stock Holding History

ORG Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-400
Closed -$1.39K – 1261
2024
Q2 		$1.39K Buy
+400
New +$1.23K ﹤0.01% 1540
2024
Q1 		– Sell
-400
Closed -$680 – 751
2023
Q4 		$680 Buy
+400
New +$440 ﹤0.01% 1030

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ORG Partners's HRTX Position: Q3 2024 in Review

ORG Partners sold out of Heron Therapeutics (HRTX) in Q3 2024, closing a stake of 400 shares — an estimated $1.39K sold.

ORG Partners first reported a position in HRTX in Q4 2023 and held it in 2 quarters. The position peaked at $1.39K in Q2 2024. 173 funds tracked by Wall St. Rank hold HRTX as of Q3 2024.

  • ORG Partners reported no remaining Heron Therapeutics position as of Q3 2024 after selling out during the quarter.
  • ORG Partners sold 400 Heron Therapeutics shares in Q3 2024, an estimated $1.39K.
  • ORG Partners first reported a position in Heron Therapeutics in Q4 2023 and held it in 2 quarters.
  • ORG Partners's Heron Therapeutics position peaked at $1.39K in Q2 2024.
  • 173 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2024.

Based on ORG Partners's 13F filing for Q3 2024, filed 11 Oct 2024.